Compare Moderna, Inc. (MRNA) vs Western Digital Corp (WDC) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Western Digital (WDC) trades at $454.34, up 3.7% in the last 24 hours, with strong earnings beats in recent quarters and a bullish analyst consensus of 72% buy ratings. The stock faces bearish technical signals but benefits from robust AI-driven storage demand, evidenced by 44% revenue growth in Q4 2026 and a net income margin of 72.95% in 2025. Recent news highlights its positioning as a key player in AI infrastructure, though valuation concerns persist.

The outlook for WDC is positive due to sustained AI storage demand and margin expansion, but risks include high valuation multiples and cyclical industry pressures. With a consensus price target of $665.15, upside potential exists, yet investors should monitor competitive threats and earnings sustainability.